Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- Drug Discovery
- Viral Infection
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 371191
Epitopes or protein of antigens which can be utilized to develop singular or multi-targeted vaccines. Epitopes can simply be fused to the end of the S domain via flexible linker through recombinant DNA technology. Identified epitopes of limited variability in H1 influenza that have circulated throughout history (since 1918) and make ideal vaccine targets and have completed similar analysis of H3 and Flu B strains for similar epitopes which will be used to produce our lead vaccine candidate BWV-101 as a universal vaccine for influenza infection. Due to the cross-reactive nature of the H1 epitopes in pre-pandemic H1 influenza A, companies are pursuing the development of a stand-alone H1 vaccine (BWV-102). These epitopes are able to be formulated into a vaccine candidate using the VLP platform technologies and may be evaluated using other vaccine technologies through partnerships in order to accelerate development of potential vaccines or to explore adjunct therapies.
Field of use is for the treatment of influenza.
IPSCIO Record ID: 4244
VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Companyâ€™s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.
The Licensorâ€™s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).
The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.
IPSCIO Record ID: 379884
An exclusive license under the Patents to (a) Develop, make, lease, sell, license, or otherwise distribute Products; and (b) Practice the Processes solely as necessary for the exercise of the foregoing rights.
A non-exclusive limited license to use and copy the Technology internally solely as necessary for the use or practice of the Patents. Hospital will deliver a copy of the Technology to Licensee at a time mutually agreed to by the parties and will have no obligation to update the Technology at any later period.
U.S. Patent 9,096,644, entitled â€œAntigen-Norovirus P-Domain Monomers and Dimers, Antigen-Norovirus P-Particle Molecules, and Methods of Their Making and Useâ€, filed on Jun. 9, 2009, with a priority date of Jul. 10, 2009.
US Patent No 9,562,077, entitled â€œProtein Complex System for Increased Immunogenicity and Functionality, and Methods Making and Useâ€, filed on Mar. 14, 2013, with priority date July 11, 2012 (Provisional Application No. 61/670,288).
IPSCIO Record ID: 299287
The patents include Improved vaccines and methods for using the same; Novel vaccines against multiple subtypes of influenza virus; Influenza Nucleic acid molecules and vaccines made therefrom; and, Nucleic acid molecule encoding concensus influenza a hemagglutinin H!
SynConâ„¢ technology enables the design of â€œuniversalâ€ DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza.
IPSCIO Record ID: 324645
8,114,407 – EphA2 T-cell epitopes and uses therefor
Proprietary Vaccine shall mean a vaccine which is developed or being developed for a therapeutic indication based on biological activity that is solely-owned or in-licensed by Licensee from third parties and which is not covered by the Patent Rights and which is not Licensed Product hereunder. For the avoidance of doubt, the Il-13 Alpha2 Peptide Analogues licensed under the Exclusive Patent License Agreement shall constitute a Proprietary Vaccine.
IPSCIO Record ID: 27555
A Sublicence under the Licence may be granted by the Licensee only with the prior written consent of the Licensor.
IPSCIO Record ID: 298360
Licensor is is a clinical-stage biopharmaceutical company with expertise in the pre-clinical and clinical development of pharmaceutical products.
Licensed Product means products and services that are made, made for, used, imported, offered for sale or sold by Company or its Affiliates or sublicensees in the field.
â€¢VaxCelerate offers two unique elements to combat the Coronavirus – one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy.
The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack.
Field shall mean all products and processes or uses developed hereunder, whether or not related to the Patent Rights, for the prevention, interception or treatment of COVID-19 and other related corona viruses, or otherwise.
IPSCIO Record ID: 336310
For greater particularity and notwithstanding the foregoing, this license is non-exclusive as to its use for diagnostic applications for Pasteurella haemolytica or Bovine Herpes Virus-1 antibodies.
Licensed Patents include Adjuvant Formulation with Enhanced Immunogenic Activity, and Related Compositions and Methods; Nucleotide Sequences Encoding Recombinant Bovine Herpesvirus Type 1, gl, gill, gIV Polypeptides; Bovine Herpesvirus Type 1 Polypeptides and Vaccines; Compositions and Treatments for Pneumonia in Animals, and other related patents.
Myostatin Product means a Product that comprises myostatin also known as growth differentiating factor 8 (GDF-8) protein, peptide or nucleic acid.
IPSCIO Record ID: 375061
BWV-201 is a live attenuated serotype-independent intranasal vaccine candidate for S. pneumoniae induced AOM (Acute Otitis Media). BWV-201 has the ability to transiently colonize the nasopharyngeal cavity and significantly decrease the incidence of AOM and sinusitis in animal models. The vaccine candidate is derived from the noninvasive serotype 19F strain BHN97.
9,265,819 – Live, attenuated Streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
Streptococcus pneumoniae is the main cause of community acquired pneumonia and meningitis in children and the elderly, and of sepsis in those infected with HIV.
IPSCIO Record ID: 305790
Licensor is a clinical stage, publicly-traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Licensors proprietary XpressCF platform technology) to advance next-generation oncology therapeutics.
The primary invention underpinning the XpressCF platform was the creation of engineered E.coli-derived proprietary extracts containing fully functional oxidative phosphorylation machinery in inverted membrane vesicles and orthogonal tRNA capable of catalyzing nnAA incorporation. This innovation enables the Extract to regenerate high energy phosphates required for protein translation and nnAA incorporation, reducing production cost and permitting the use of industrial sized reaction vessels and longer manufacturing run times than previously thought possible. The XpressCF system routinely produces g/L of complex proteins in 8-10 hours and scales linearly from bench to large-scale GMP production. The protein of interest is produced at high yield and the absence of cellular debris combine to simplify downstream purification, further enhancing production efficiency.
XpressCFâ„¢, an industrialized cell-free protein synthesis platform, for the vaccine field allowing (1) site-specific conjugation; (2) production of complex antigens in more optimal conformation; and (3) speed, flexibility and scalability of the discovery engine.
The XpressCF platform overcomes these significant limitations by separating the precise cellular machinery required for transcription, translation, and energy production into an E.coli-derived mixture, or Extract capable of continuous oxidative phosphorylation.
Licensee is a next-generation vaccine company whose cell-free protein synthesis platform enables the design and production of optimized protein carriers and antigens, the critical building blocks of vaccines.
IPSCIO Record ID: 308732
The College grants to Licensee a non-exclusive, worldwide, license under its rights in and to the College Technology Transfer Materials solely for use in identifying, discovering, developing, making, having made, using, marketing, offering for sale, selling, having sold and importing any Type I Licensed Product or Type II Licensed Product.
Type I Licensed Product shall mean any product, the manufacture, use, sale, marketing or importation of which falls within the scope of a Valid Claim in the country in which it is manufactured, used, sold, marketed or imported. Type II Licensed Product' shall mean any product that is not a Type I Licensed Product, but is identified or discovered through the use of a Licensed Method.
Licensed Services shall mean any service provided for or on behalf of a third party on a fee-for-service basis that entails the practice of a Licensed Method.
Materials transferred include
– Chlamydia libraries (donor library and expression library with and without cLLO)
– pDEST-SL8 expression vector
– Plasmids and E. Coli Strains
– T cell Lines
– Other Cell Lines, and,
– Protocols as follows
1. Gateway cloning
2. CE6 phage prep
3. Library induction
4. Library screening
5. Chlamydia growth and prep
6. T cell expansion (multiple protocols)
7. APC preps
8. Chlamydia infection ( cell line and mouse)
9. B3Z assay for library validation
10. ICS assay for antigen presentation
Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.
IPSCIO Record ID: 27993
The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like FluogenÂ®, which includes a proprietary adjuvant developed by Licensor.
IPSCIO Record ID: 367304
IPSCIO Record ID: 248399
Plague Vaccine Dose shall mean a dose of recombinant protective antigen plague vaccine the manufacture, use, sale, keeping1 importing or exporting of which would, lo the absence of the license granted under this Agreement, constitute an infringement or actionable misuse of the Vaccine IP.
Patents are for Plague vacclnes and Vaccine Compositions.
The use beyond the United States is for inter alia the development of a prototype recombinant protective antigen plague vaccine and the production of trials doses thereof.
IPSCIO Record ID: 4747
Pursuant to the License Agreement, Licensee has an exclusive worldwide License to develop, manufacture and market HPV-16 VLP vaccines for the prevention and/or treatment of HPV infection, except that Licensor retained the right to co-market the product in the United States, including Puerto Rico.
IPSCIO Record ID: 319599
Licensor hereby grants to Licensee the exclusive option to enter into a license agreement from Licensor for the commercial development, use, and sale of the Technology, products based on the Technology, patents, trade secrets, know-how, and other information related to the Technology;
Materials shall mean the materials and/or intellectual property listed
– Licensor IDF Number 2013-2417 entitled â€œNon-Covalent Loading of Plant Picornavirus Particlesâ€ with US Patent Application US2015/0376578 A1 and EP Patent Application 14754692.3
– Licensor IDF Number 2015-2767 entitled â€œCancer Immunotherapy using Virus Particles with US Patent Application US2018/0133304 A1 and associated foreign patent applications in Japan, China, Canada, Australia, and EP, US non-published patent application with patent serial number 16/612,214, and PCT Patent application with publication number WO 2018/208828 A1
– Licensor IDF Number 2017-3151 entitled â€œMelt Processed Viral Nanoparticle Constructsâ€ with US Patent Application US2019/0350871 A1 and EP Patent Application 17868454.4
Patents shall mean any patent that issues or has issued to Licensor or patent application covering or consisting of the Technology and based on intellectual property in existence as of the Effective Date and any related patent or patent application that is a continuation, continuation-in-part, divisional, or reissue in the United States of America or any other country.
The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19.
The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.
This immuno-oncology approach provides a personalized treatment approach by relieving the patientâ€™s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor.
The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.
Field of Use shall mean all therapeutic, diagnostic, vaccine and preventive uses of Technology for both veterinary and human applications. Final field of use, including specific indications, which may be narrower than the Field of Use, will be defined in any commercial use license. Said commercial use license will necessarily incorporate developmental, regulatory, and commercial distribution/sales milestones for each product that incorporates any Technology in the Field of Use. For clarification purposes, Technology and Materials shall not be used in or on humans during the Evaluation Period unless Licensee consults with Licensor regarding appropriate, and possibly expanded, indemnification and insurance requirements and receives Licensorâ€™s written authorization to do so. Such authorization will be in Licensorâ€™s sole discretion.
IPSCIO Record ID: 113052
The company is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments BioTherapeutics and Vaccines/BioDefense.
The Companyâ€™s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (â€œCTCLâ€), proprietary formulations of oral beclomethasone 17, 21-dipropionate (â€œBDPâ€) for the prevention/treatment of gastrointestinal (â€œGIâ€) disorders characterized by severe inflammation, including pediatric Crohnâ€™s disease (SGX203) and acute radiation enteritis (SGX201), and itâ€™s novel innate defense regulator (â€œIDRâ€) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
The Companyâ€™s Vaccines/BioDefense business segment includes active development programs for RiVaxâ„¢, its ricin toxin vaccine candidate, VeloThraxâ„¢, an anthrax vaccine candidate, OrbeShieldÂ®, a GI acute radiation syndrome (â€œGI ARSâ€) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVaxÂ®, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), the Company will attempt to advance the development of RiVaxâ„¢ to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (â€œBARDAâ€) and NIAID to advance the development of OrbeShieldÂ® for the treatment of GI ARS.
IPSCIO Record ID: 253954
For the Licenses for Collaboration Patents the Australian Licensors grants a nonexclusive, worldwide license, with the right to sublicense, under any Collaboration Patents that are owned solely by Licensor.
For the License for Licensed Products the Licensor grants to an exclusive license under the Licensed Subject Matter to develop, make, have made, use, offer to sell, sell, have sold and import Licensed Products within the Licensed Territory for use within the Licensed Field.
Virus-like particles (VLPs) in their second-generation application are constructs that can be engineered to carry foreign antigens on their surface and mimic viruses in their ability to stimulate strong immune responses, in this case against foreign antigens.
The research and development (R&D) partnership focused on the use of Select Vaccinesâ€™ virus-like particles (VLPs) as a platform technology for the development of viral vaccines. The R&D efforts will initially target the development of vaccines against influenza including both epidemic and pandemic forms of vaccine, with the opportunity to expand the collaboration to other disease targets.
IPSCIO Record ID: 328343
AIDS Vaccine means a vaccine which would prevent an infection by Human Immunodeficiency Virus (HIV-1) and/or clinical diseases caused by infection with HIV-1 in humans.
Influenza Vaccine means a vaccine which would prevent an infection and/or significant clinical diseases caused by any influenza virus in humans.
Licensed Product means a bulk or finished AIDS Vaccine or Influenza Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program; provided, however, that if any such vaccine is also capable of being used for treatment of the same human infectious disease, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement.
IPSCIO Record ID: 305251
Premas vaccine platform is certain patent applications, know-how and other proprietary information related to a vaccine platform that involves genetically engineered and modified yeast, Saccharomyces cerevisiae, which along with certain proprietary expression vectors and optimized genes developed to be used with the above strain, and, has been shown to be useful in the expression of more than thirty type 1 endoplasmic reticulum associated proteins.